The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Open accessAbstract
There has been a revolution in nanotechnology and nanomedicine. Since 1980, there has been a remarkable increase in approved nano-based pharmaceutical products. These novel nano-based systems can either be therapeutic agents themselves, or else act as vehicles to carry different active pharmaceutical agents into specific parts of the body. Currently marketed nanostructures include nanocrystals, liposomes and lipid nanoparticles, PEGylated polymeric nanodrugs, other polymers, protein-based nanoparticles and metal-based nanoparticles. A range of issues must be addressed in the development of these nanostructures. Ethics, market size, possibility of market failure, costs and commercial development, are some topics which are on the table to be discussed. After passing all the ethical and biological assessments, and satisfying the investors as to future profitability, only a handful of these nanoformulations, successfully obtained marketing approval. We survey the range of nanomedicines that have received regulatory approval and are marketed. We discuss ethics, costs, commercial development and possible market failure. We estimate the global nanomedicine market size and future growth. Our goal is to summarize the different approved nanoformulations on the market, and briefly cover the challenges and future outlook.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–233 of 233
Hogan, A. C. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.063024 · Cited by 36
Importance of Nanosensors: Feynman's Vision and the Birth of Nanotechnology
Devreese, J. T. (2007) · MRS Bulletin · doi:10.1557/mrs2007.147 · Cited by 36
Smart Stimuli-Responsive Nano-sized Hosts for Drug Delivery
Hosseini, M. H., Farjadian, F., & Hamdy, A. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-26893-4_1 · Cited by 36
Self-citationNanomaterial Drug Products: Manufacturing and Analytical Perspectives
Sayes, C. M., Aquino, G. V., & Hickey, A. J. (2016) · The AAPS Journal · doi:10.1208/s12248-016-0008-x · Cited by 36
Farjadian, F., Ghasemi, S., Heidari, R., & Mohammadi‐Samani, S. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.10.012 · Cited by 35
Self-citationAndrews, P. L. R., Kovacs, M., & Watson, J. W. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02269-8 · Cited by 34
Microstructure and chemistry affects apatite nucleation on calcium phosphate bone graft substitutes
Campion, C. R., Ball, S. L., Clarke, D. L., & Hing, K. A. (2012) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-012-4833-x · Cited by 32
Duvic, M. A. (2000) · Clinical Lymphoma · doi:10.3816/clm.2000.s.010 · Cited by 31
Transdermal menopausal hormone therapy: delivery through skin changes the rules
Buster, J. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003774098 · Cited by 31
Pegaptanib sodium for ocular vascular disease
Cunningham, E. T., Shukla, D., Namperumalsamy, P., & Goldbaum, M. (2007) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.36476 · Cited by 29
Liposome-coated lipoplex–based carrier for antisense oligonucleotides
Wyrozumska, P., Meissner, J. M., Toporkiewicz, M., Szarawarska, M., Kuliczkowski, K., Ugorski, M., Walasek, M. A., & Sikorski, A. F. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.987009 · Cited by 29
How do we develop nanopharmaceuticals under open innovation?
Eaton, M. A. W. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.05.015 · Cited by 28
Fatehi, L., Wolf, S. M., McCullough, J., Hall, R., Lawrenz, F. P., Kahn, J. P., Jones, C. M., Campbell, S. A., Dresser, R. S., Erdman, A. G., et al. (2012) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2012.00703.x · Cited by 27
Zhang, R., Saito, R., Mano, Y., Sumiyoshi, A., Kanamori, M., Sonoda, Y., Kawashima, R., & Tominaga, T. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1081994 · Cited by 25
Glatiramer Acetate 40 mg/mL in Relapsing–Remitting Multiple Sclerosis: A Review
McKeage, K. (2015) · CNS Drugs · doi:10.1007/s40263-015-0245-z · Cited by 25
Takemoto, K., & Kanazawa, K. (2016) · Journal of Liposome Research · doi:10.1080/08982104.2016.1205087 · Cited by 25
Why I’m Holding onto Hope for Nano in Oncology
Allen, C. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00547 · Cited by 24
Wang, Y., Ding, Y., Liu, Z., Liu, X., Chen, L., & Yan, W. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1121-5 · Cited by 23
Nanomedicines in the treatment of acromegaly: focus on pegvisomant
Roelfsema, F., Biermasz, N. R., Pereira, A. M., & Romijn, J. A. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.4.385 · Cited by 23
On the Development of Antifungal Agents: Perspective of the U.S. Food and Drug Administration
Wu, T. C. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.supplement_1.s54 · Cited by 23
Evolving Complexity in Hemophilia Management
Croteau, S. E. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.004 · Cited by 20
Nonsurgical Management of Osteoarthritis Knee Pain in the Older Adult
Taylor, N. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.03.009 · Cited by 20
Nanopharmaceuticals: Challenges and Regulatory Perspective
Shah, R. B., & Khan, M. A. (2008) · Springer eBooks · doi:10.1007/978-0-387-77668-2_21 · Cited by 19
Daunorubicin & Cytarabine Liposome (Vyxeos™)
Crain, M. L. (2018) · Oncology Times · doi:10.1097/01.cot.0000534146.30839.ec · Cited by 17
Toxicity assessment of nanopharmaceuticals
Erkekoğlu, P., & Kocer-Gumusel, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813661-4.00013-4 · Cited by 15
FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.
(1996) · PubMed · Cited by 14
Satalkar, P. P., Elger, B. S., & Shaw, D. (2016) · Nanomedicine · doi:10.2217/nnm-2015-0003 · Cited by 12
Parpura, V. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.123 · Cited by 11
Wolf, S. M. (2012) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2012.00702.x · Cited by 10
Applying the best of oncology drug development paradigms to the non-malignant space
Bhattacharya, I., Heatherington, A. C., & Barton, J. E. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.031 · Cited by 5
Woods, G. M., Dunn, M. W., & Dunn, A. L. (2018) · Clinical Pediatric Emergency Medicine · doi:10.1016/j.cpem.2018.05.004 · Cited by 5
Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?
Mott, T. F., Leach, L. M., & Johnson, L. A. (2004) · PubMed · Cited by 4
Turanlı, E. T., & Everest, E. (2015) · Nanoscience and technology · doi:10.1007/978-3-319-25340-4_23 · Cited by 3
Cited by
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Effects of nanoparticle size, shape, and zeta potential on drug delivery
Öztürk, K., Kaplan, M., & Çalış, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124799 · Cited by 449
Supramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
Biocompatibility of nanomaterials and their immunological properties
Kyriakides, T. R., Raj, A., Tseng, T. H., Xiao, H., Nguyen, R., Mohammed, F. S., Halder, S., Xu, M., Wu, M. J., Bao, S., et al. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe5fa · Cited by 389
Overcoming barriers by local drug delivery with liposomes
Antimisiaris, S. G., Marazioti, A., Kannavou, M., Natsaridis, E., Gkartziou, F., Kogkos, G., & Mourtas, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.019 · Cited by 339
Metadata
- Authors
- Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-11-19
- Volume
- 14
- Issue
- 1
- Pages
- 93-126
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2901675852
- Cited by
- 664
- References
- 233
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.